US › Healthcare

Nautilus Biotechnology Inc (NAUT)

US · Healthcare · Biotechnology

$2.06-4.63%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$190,000

Net profit

$-14.5M

EPS

$-0.11

EPS estimate

$-0.14

Net margin

-7,615.3%

EPS came in at -0.11 against a street estimate of -0.14 — a beat of 21.4%.

Key statistics

Market cap

$262.1M

Forward P/E

0.0

P/B

0.93

Book value

$1.03

EPS (TTM)

$-0.45

52-week high

$4.31

52-week low

$0.84

50-day MA

$1.21

200-day MA

$2.08

Beta

0.73

Analyst view

Analysts rate Nautilus Biotechnology Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $3.83.

Shareholding

Insiders

32.02%

Institutions

43.04%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	9.14%
Cercano Management LLC	5.64%
BlackRock Inc	2.11%
Vanguard Capital Management, LLC	2.00%
Comprehensive Financial Management LLC	1.73%
Citadel Advisors Llc	1.49%
Geode Capital Management, LLC	0.99%
Acadian Asset Management LLC	0.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nautilus Biotechnology Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.